Johanna Roberts - Penumbra President

PEN Stock  USD 244.15  4.81  1.93%   

President

Ms. Johanna Roberts is Executive Vice President, General Counsel, Secretary of the Company. She joined Penumbra in 2014. She served as Vice President and Deputy General Counsel from July 2015 until her promotion to Executive Vice President and General Counsel in September 2018. Prior to joining Penumbra, Ms. Roberts had fifteen years experience working for several law firms, including Morrison Foerster LLP in San Francisco since 2018.
Age 52
Tenure 6 years
Address One Penumbra Place, Alameda, CA, United States, 94502
Phone510 748 3200
Webhttps://www.penumbrainc.com

Latest Insider Transactions

2024-11-18Disposed of 600 shares @ 239.74View
2024-10-01Disposed of 600 shares @ 190.76View
2024-09-03Disposed of 600 shares @ 206.22View
2024-08-13Disposed of 600 shares @ 175.98View
2024-06-03Disposed of 600 shares @ 188.9View
2024-05-13Disposed of 600 shares @ 207.41View
2024-04-01Disposed of 600 shares @ 217.07View
Roberts received a B.A. from Dartmouth College and J.D. from Harvard Law School.

Johanna Roberts Latest Insider Activity

Tracking and analyzing the buying and selling activities of Johanna Roberts against Penumbra stock is an integral part of due diligence when investing in Penumbra. Johanna Roberts insider activity provides valuable insight into whether Penumbra is net buyers or sellers over its current business cycle. Note, Penumbra insiders must abide by specific rules, including filing SEC forms every time they buy or sell Penumbra'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Penumbra Management Efficiency

The company has Return on Asset of 0.0333 % which means that on every $100 spent on assets, it made $0.0333 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0313 %, implying that it generated $0.0313 on every 100 dollars invested. Penumbra's management efficiency ratios could be used to measure how well Penumbra manages its routine affairs as well as how well it operates its assets and liabilities. As of the 28th of November 2024, Return On Tangible Assets is likely to grow to 0.07. Also, Return On Capital Employed is likely to grow to 0.06. At this time, Penumbra's Return On Assets are very stable compared to the past year. As of the 28th of November 2024, Asset Turnover is likely to grow to 0.88, while Other Assets are likely to drop about 47.4 M.
Penumbra has 234.34 M in debt with debt to equity (D/E) ratio of 0.23, which may show that the company is not taking advantage of profits from borrowing. Penumbra has a current ratio of 4.83, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Note however, debt could still be an excellent tool for Penumbra to invest in growth at high rates of return.

Similar Executives

Found 2 records

PRESIDENT Age

Paul HickeyReShape Lifesciences
59
Naqeeb AnsariReShape Lifesciences
63
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California. Penumbra operates under Medical Devices classification in the United States and is traded on New York Stock Exchange. It employs 3800 people. Penumbra (PEN) is traded on New York Stock Exchange in USA. It is located in One Penumbra Place, Alameda, CA, United States, 94502 and employs 4,200 people. Penumbra is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Management Performance

Penumbra Leadership Team

Elected by the shareholders, the Penumbra's board of directors comprises two types of representatives: Penumbra inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Penumbra. The board's role is to monitor Penumbra's management team and ensure that shareholders' interests are well served. Penumbra's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Penumbra's outside directors are responsible for providing unbiased perspectives on the board's policies.
Ben Tompkins, Executive Development
Surbhi Sarna, Independent Director
Bridget ORourke, Independent Director
Adam Elsesser, Chairman of the Board, Chief Executive Officer
James Pray, President International
Shruthi Narayan, Executive Interventional
Gita Barry, President Healthcare
Holly Sit, Director Development
Lynn Rothman, Executive Vice President, Chief Business Officer
Arani MD, CoFounder Director
Pankaj Tiwari, Executive Officer
Harpreet Grewal, Independent Director
Maggie Yuen, Chief Financial Officer
Jee HamlynHarris, Investor Officer
Don Kassing, Presiding Independent Director
Adam JD, Chairman, CoFounder
Ben Sorci, Executive Operations
Lambert Shiu, Chief Accounting Officer
Johanna Roberts, Executive Vice President General Counsel, Secretary
MD FSIR, Chief Officer
Jason Mills, Executive Strategy
Thomas Wilder, Independent Director
Sandra Lesenfants, President Interventional
Arani Bose, Executive Director and Chief Innovator
Johanna JD, General VP
Janet Leeds, Lead Independent Director

Penumbra Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Penumbra a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Penumbra

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Penumbra position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Penumbra will appreciate offsetting losses from the drop in the long position's value.

Moving together with Penumbra Stock

  0.81LH LaboratoryPairCorr
  0.9VREX Varex Imaging CorpPairCorr

Moving against Penumbra Stock

  0.95TFX Teleflex IncorporatedPairCorr
  0.89GCTK GlucoTrackPairCorr
  0.87ZJYL JIN MEDICAL INTERNATIONALPairCorr
  0.82XTNT Xtant Medical HoldingsPairCorr
  0.79CNC Centene Corp Sell-off TrendPairCorr
The ability to find closely correlated positions to Penumbra could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Penumbra when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Penumbra - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Penumbra to buy it.
The correlation of Penumbra is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Penumbra moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Penumbra moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Penumbra can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Penumbra offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Penumbra's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Penumbra Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Penumbra Stock:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Penumbra. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.
To learn how to invest in Penumbra Stock, please use our How to Invest in Penumbra guide.
You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Penumbra. If investors know Penumbra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Penumbra listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
2.261
Earnings Share
0.88
Revenue Per Share
30.081
Quarterly Revenue Growth
0.111
Return On Assets
0.0333
The market value of Penumbra is measured differently than its book value, which is the value of Penumbra that is recorded on the company's balance sheet. Investors also form their own opinion of Penumbra's value that differs from its market value or its book value, called intrinsic value, which is Penumbra's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Penumbra's market value can be influenced by many factors that don't directly affect Penumbra's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Penumbra's value and its price as these two are different measures arrived at by different means. Investors typically determine if Penumbra is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Penumbra's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.